ID: ALA8013

Max Phase: Preclinical

Molecular Formula: C5H9N2Na2O5P

Molecular Weight: 210.13

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  N=C(CP(=O)([O-])[O-])NCCC(=O)O.[Na+].[Na+]

Standard InChI:  InChI=1S/C5H11N2O5P.2Na/c6-4(3-13(10,11)12)7-2-1-5(8)9;;/h1-3H2,(H2,6,7)(H,8,9)(H2,10,11,12);;/q;2*+1/p-2

Standard InChI Key:  MVKVWRBTZBSAEB-UHFFFAOYSA-L

Associated Targets(Human)

Creatine kinase M 67 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 210.13Molecular Weight (Monoisotopic): 210.0406AlogP: -0.79#Rotatable Bonds: 5
Polar Surface Area: 130.71Molecular Species: ZWITTERIONHBA: 3HBD: 5
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 5#RO5 Violations (Lipinski): 0
CX Acidic pKa: 0.52CX Basic pKa: 12.28CX LogP: -2.52CX LogD: -6.00
Aromatic Rings: 0Heavy Atoms: 13QED Weighted: 0.23Np Likeness Score: 0.17

References

1. Bergnes G, Kaddurah-Daouk R.  (1997)  Synthesis and creatine kinase inhibitory activity of non-hydrolyzable analogs of phosphocreatine,  (8): [10.1016/S0960-894X(97)00161-3]

Source